Caption Management’s Summit Therapeutics SMMT Stock Holding History

Caption Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.36M	Sell	230,000 -10,000	-4%	-$162K	0.03%	570
2025 Q4	$4.2M	Buy	240,000 +34,500	+17%	+$649K	0.03%	573
2025 Q3	$4.25M	Buy	205,500 +42,000	+26%	+$1.02M	0.03%	555
2025 Q2	$3.48M	Buy	163,500 +153,500	+1,535%	+$3.5M	0.04%	521
2025 Q1	$193K	Buy	+10,000	New	+$201K	﹤0.01%	1280
2024 Q3	–	Sell	-499,100	Closed	-$3.89M	–	1575
2024 Q2	$3.89M	Buy	+499,100	New	+$2.7M	0.06%	324

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Caption Management's SMMT Position: Q4 2025 in Review

Caption Management sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 28,264 shares — an estimated $532K sold.

Caption Management first reported a position in SMMT in Q2 2025 and held it in 2 quarters. The position peaked at $5.69M in Q2 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

Caption Management reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
Caption Management sold 28,264 Summit Therapeutics shares in Q4 2025, an estimated $532K.
Caption Management first reported a position in Summit Therapeutics in Q2 2025 and held it in 2 quarters.
Caption Management's Summit Therapeutics position peaked at $5.69M in Q2 2025.
206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.